mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia

We have previously demonstrated that mTOR inhibitors (MTIs) are active in preclinical models of acute lymphoblastic leukemia (ALL). MTIs may increase degradation of cyclin D1, a protein involved in dihydrofolate reductase (DHFR) synthesis. Because resistance to methotrexate may correlate with high D...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Teachey, David T., Sheen, Cecilia, Hall, Junior, Ryan, Theresa, Brown, Valerie I., Fish, Jonathan, Reid, Gregor S. D., Seif, Alix E., Norris, Robin, Chang, Yueh J., Carroll, Martin, Grupp, Stephan A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2008
Assuntos:
Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2518903/
https://ncbi.nlm.nih.gov/pubmed/18544682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-02-137141
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados